清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma

无容量 医学 易普利姆玛 中止 内科学 不利影响 间皮瘤 外科 胃肠病学 肿瘤科 免疫疗法 癌症 病理
作者
D. Dumoulin,Li-Anne H Douma,M.M. Hofman,Vincent van der Noort,Robin Cornelissen,Cornedine J. de Gooijer,Jacobus A. Burgers,Joachim Aerts
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:187: 107440-107440
标识
DOI:10.1016/j.lungcan.2023.107440
摘要

ObjectivesNivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is a new first-line treatment combination for patients with pleural mesothelioma. Nivolumab-ipilimumab improved the survival, however, 30.3% of the patients suffered from grade 3–4 treatment related adverse events (TRAE’s) and TRAE’s led to discontinuation in 23.0% of all patients. Here, we present the first real-world data of nivolumab plus ipilimumab in patients with malignant mesothelioma treated in two mesothelioma expert centers.MethodsClinical data of patients with mesothelioma treated with nivolumab and ipilimumab were prospectively collected. Clinical parameters were obtained every visit, CT scans were evaluated every 12 weeks and adverse events were assessed continuously during the treatment. Data on grade 2–5 TRAE’s and activity (overall response rate (ORR), duration of response (DOR), disease control rate (DCR), median progression-free survival (mPFS) and median overall survival (mOS) were reported.ResultsBetween January 2021 and August 2022, 184 patients were treated with nivolumab plus ipilimumab. The median follow-up was 12.1 months (95 %CI 11.1 – 13.1). Grade 3–4 TRAEs were seen in 27.7 % of the patients and 25.0 % discontinued immunotherapy treatment early because of TRAE’s. ORR was 21.7 % (95 % CI 15.7–27.7), median DOR was 5.7 months (IQR 3.2–8.7) and DCR at 12 weeks 56.0 % (95 % CI 48.8–63.2). The mPFS was 5.5 months (95 %CI 4.1–6.9), mOS was 14.1 months (95 % CI 11.1–18.2).ConclusionsNivolumab plus ipilimumab had an equal efficacy in a real-world comparable population but also a high risk of TRAE’s, leading to discontinuation of treatment in 25% of the patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cadcae完成签到,获得积分10
28秒前
GYQ完成签到,获得积分20
28秒前
光合作用完成签到,获得积分10
31秒前
yueyueyahoo完成签到,获得积分10
41秒前
47秒前
呆呆的猕猴桃完成签到 ,获得积分10
1分钟前
1111完成签到 ,获得积分10
1分钟前
今后应助傲娇的夜山采纳,获得10
1分钟前
cgs完成签到 ,获得积分10
1分钟前
zpc猪猪完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
Akim应助科研通管家采纳,获得10
1分钟前
柯伊达完成签到 ,获得积分10
2分钟前
elisa828完成签到,获得积分10
2分钟前
2分钟前
2分钟前
喵叽发布了新的文献求助10
2分钟前
桐桐应助喵叽采纳,获得10
3分钟前
平平平平完成签到 ,获得积分10
3分钟前
rockyshi完成签到 ,获得积分10
3分钟前
3分钟前
新新新新新发顶刊完成签到 ,获得积分10
3分钟前
科目三应助科研通管家采纳,获得10
3分钟前
柚子完成签到 ,获得积分20
4分钟前
柚子关注了科研通微信公众号
4分钟前
猪嗝铁铁完成签到,获得积分10
4分钟前
文静如南完成签到 ,获得积分10
4分钟前
003完成签到,获得积分10
4分钟前
5分钟前
5分钟前
无悔完成签到 ,获得积分10
5分钟前
001完成签到,获得积分10
5分钟前
5分钟前
5分钟前
喵叽发布了新的文献求助10
5分钟前
锅包肉完成签到 ,获得积分10
5分钟前
002完成签到,获得积分10
5分钟前
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
CodeCraft应助科研通管家采纳,获得10
5分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968520
求助须知:如何正确求助?哪些是违规求助? 3513331
关于积分的说明 11167298
捐赠科研通 3248700
什么是DOI,文献DOI怎么找? 1794417
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664